[Newsmp] The Ministry of Food and Drug Safety on the 3rd announced the approval of the new psoriasis drug Sotyktu (ingredient: deucravacitinib) imported by BMS Korea.
Sotyktu is an oral psoriasis drug that selectively targets and inhibits TYK2, a protein that plays a key role in the immune system.
"We expect that this drug will provide a new treatment opportunity for adults with moderate to severe plaque psoriasis who need phototherapy or systemic therapy," said the representative at MFDS. “We will continue to do our best to ensure that safe and effective treatments are available to patients as quickly as possible, based on our regulatory science expertise.”
저작권자 © 의약뉴스 무단전재 및 재배포 금지
